Demographic features of HIV-1 infected patients, exposed seronegative donors and healthy controls.

aPatients in HAART treatment were using combinations of nucleoside reverse transcriptase inhibitors (abacavir, lamivudine, didanosine, stavudine, and zidovudine), nonnucleoside reverse transcriptase inhibitors (efavirenz and nevirapine), and protease inhibitors (lopinavir, fosamprenavir, amprenavir, nelfinavir, and saquinavir).bCD4+ T cell counts under 200 cells/ll, were receiving fluconazol, acliclovir, and TMS as prophylactic drugs.HAART, highly active antiretroviral therapy; N/A, not applicableDemographic features of HIV-1 infected patients, exposed seronegative donors and healthy controls.